Moreover, the 36-month beta value for TOVX is 1.18. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TOVX is 2.75M and currently, short sellers hold a 9.53% of that float. On February 14, 2025, TOVX’s average trading volume was 468.98K shares.
TOVX) stock’s latest price update
Theriva Biologics Inc (AMEX: TOVX)’s stock price has gone rise by 12.42 in comparison to its previous close of 1.53, however, the company has experienced a 16.22% increase in its stock price over the last five trading days. globenewswire.com reported 2024-12-05 that ROCKVILLE, Md., Dec. 05, 2024 (GLOBE NEWSWIRE) — Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the outcomes of a recent Type D meeting with the U.S. Food and Drug Administration (FDA) to obtain guidance on the design of a Phase 3 clinical study of lead clinical candidate VCN-01 in combination with standard-of-care chemotherapy for the treatment of metastatic pancreatic adenocarcinoma (PDAC). The Company recently announced the completion of target enrollment into the multinational VIRAGE Phase 2b clinical study evaluating intravenous VCN-01 in combination with gemcitabine/nab-paclitaxel as a first line therapy for PDAC patients.
TOVX’s Market Performance
Theriva Biologics Inc (TOVX) has experienced a 16.22% rise in stock performance for the past week, with a -9.95% drop in the past month, and a -7.53% drop in the past quarter. The volatility ratio for the week is 7.81%, and the volatility levels for the past 30 days are at 8.28% for TOVX. The simple moving average for the past 20 days is 22.03% for TOVX’s stock, with a -56.18% simple moving average for the past 200 days.
TOVX Trading at 22.02% from the 50-Day Moving Average
After a stumble in the market that brought TOVX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.95% of loss for the given period.
Volatility was left at 8.28%, however, over the last 30 days, the volatility rate increased by 7.81%, as shares surge +13.91% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +19.44% upper at present.
During the last 5 trading sessions, TOVX rose by +16.22%, which changed the moving average for the period of 200-days by -83.60% in comparison to the 20-day moving average, which settled at $1.4095. In addition, Theriva Biologics Inc saw -1.71% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for TOVX
Current profitability levels for the company are sitting at:
- -36.47 for the present operating margin
- 0.85 for the gross margin
The net margin for Theriva Biologics Inc stands at -35.21. The total capital return value is set at -0.84. Equity return is now at value -77.91, with -52.52 for asset returns.
Based on Theriva Biologics Inc (TOVX), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -10.8. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -67.76.
Currently, EBITDA for the company is -19.85 million with net debt to EBITDA at 0.7. When we switch over and look at the enterprise to sales, we see a ratio of -13.04. The receivables turnover for the company is 0.38for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.67.
Conclusion
To wrap up, the performance of Theriva Biologics Inc (TOVX) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
